Vapotherm Inc.

107 articles with Vapotherm Inc.

• Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results

  2/23/2023

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced fourth quarter and fiscal year 2022 financial results.

• Vapotherm Announces Closing of $23 Million Private Placement

  2/14/2023

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”) today announced that it closed its previously announced private placement on February 10, 2023, for the issuance and sale of 17,502,244 shares of its common stock and pre-funded warrants to purchase up to 4,402,508 shares of its common stock.

• Vapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash Balance

  2/8/2023

  Vapotherm, Inc. today announced preliminary unaudited fourth quarter and full year 2022 net results.

• Vapotherm Announces $23 Million Private Placement

  2/8/2023

  Vapotherm, Inc. today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with a select group of institutional and accredited investors through a private placement financing (“PIPE”) for gross proceeds of approximately $23.0 million, before deducting fees to the placement agent and other offering expenses.

• Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

  12/6/2022

  Vapotherm, Inc. announced that it was notified on November 30, 2022 by the New York Stock Exchange, Inc. that the Company is not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period.

• Vapotherm Announces Amendment to Debt Agreement

  11/22/2022

  2023 Revenue Covenant tied to percentage of Company’s annual operating plan and substantially waived if Company raises $15 million of new funding.

• Vapotherm Reports Third Quarter 2022 Financial Results

  11/2/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced third quarter 2022 financial results.

• Vapotherm to Report Third Quarter 2022 Financial Results

  10/26/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”) today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022.

• Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice

  10/3/2022

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that, on September 30, 2022, the Company entered into an Amendment No. 2 to Loan and Security Agreement with SLR Investment Corp., as Collateral Agent, and the lenders party thereto.

• Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference

  8/4/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd Annual Growth Conference.

• Vapotherm Reports Second Quarter 2022 Financial Results

  8/3/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2022 financial results.

• Vapotherm to Report Second Quarter 2022 Financial Results

  7/20/2022

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022.

• Vapotherm Reports First Quarter 2022 Financial Results

  5/4/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2022 financial results.

• Vapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual Guidance

  4/6/2022

  Vapotherm, Inc., announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance together with its full year 2022 gross margin, operating expense and adjusted EBITDA guidance.

• Vapotherm Launches Strategic Partnership with Carnegie Mellon University to Deliver a Tailored Artificial Intelligence (AI) Program to Drive Better Outcomes for Patients Suffering from Chronic Respiratory Diseases

  3/3/2022

  Vapotherm, Inc. announced a strategic partnership with Carnegie Mellon University, a world class AI research institution, to deliver a tailored artificial intelligence program for Vapotherm employees.

• Vapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial Results

  2/24/2022

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders announced fourth quarter and fiscal year 2021 financial results.

• Vapotherm to Report Fourth Quarter and Full Year 2021 Financial Results

  2/10/2022

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022.

• Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/22/2021

  Vapotherm, Inc. today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Vapotherm Reports Third Quarter 2021 Financial Results

  11/3/2021

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company, today announced third quarter 2021 financial results.

• Vapotherm to Report Third Quarter 2021 Financial Results

  10/20/2021

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 3, 2021.